Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a Microbiome Therapy for the Prevention of Recurrent Clostridium difficile Infection
For media inquiries, please contact: Caton Morris THRUST Investor Relations caton@thrustir.com (336) 403-0669